| Stereochemistry | ACHIRAL |
| Molecular Formula | C10H17N9O2S3 |
| Molecular Weight | 391.496 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C(N)=NS(=O)(=O)N=C1NCCSCC2=CSC(NC(N)=N)=N2
InChI
InChIKey=FSWCCDQGXZITPD-UHFFFAOYSA-N
InChI=1S/C10H17N9O2S3/c1-19-8(13)17-24(20,21)18-9(19)14-2-3-22-4-6-5-23-10(15-6)16-7(11)12/h5H,2-4H2,1H3,(H2,13,17)(H,14,18)(H4,11,12,15,16)
| Molecular Formula | C10H17N9O2S3 |
| Molecular Weight | 391.496 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Tuvatidine (HUK 978) is a potent H2-antagonist. HUK 978 was shown to be devoid of activity at the histamine H1-receptor, the muscarinic receptor and the alpha and beta-adrenergic receptors. In both the guinea-pig gastric mucosa preparation and the rat perfused stomach
model, HUK 978 was a powerful inhibitor of acid secretion. HUK 978 is a highly specific H2-antagonist and inhibits acid secretion for longer periods than other competitive compounds.
Approval Year
PubMed
Sample Use Guides
Dogs: The effect of the continuous intravenous infusion of different doses of HUK 978 (0.02 to 0.06 uM/kg/h). At doses close to the ID50 values, HUK 978 (0.07 uM/kg) gave almost twice the
inhibition at 120 min post dose compared to cimetidine.
Route of Administration:
Intragastric
Tuvatidine (HUK 978) inhibited histamine stimulated adenylate cyclase from guinea-pig
gastric fundic mucosa in a dose dependent manner. HUK 978 had no
effect on the unstimulated basal activity of adenylate cyclase. Analysis by
the method of Schild from six separate experiments gave a mean KB value of
4.8 x 10(-8) M with a slope of 1.03 showing the
antagonism to be competitive. Using membranes prepared from guinea-pig cerebral cortex,
HUK 978 inhibited 3H-tiotidine binding with a Ki of 2.0 x 10(-8) M.
